Alta Biopharma Partners III LP

This profile gathers the share dealings of Alta Biopharma Partners III LP across 6 companies, led by Aegerion Pharmaceuticals, Inc., Tvardi Therapeutics, Inc. and Viracta Therapeutics, Inc. In total, 54 filings cover trades dated from 9 January 2007 to 5 February 2014.

Both buying and selling appear: 15 purchases worth €5.8M, against 9 sales worth €5.9M. Sales outweigh purchases by €77k. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The rest of the record consists of 1 share grant. 2014 to date brings 3 purchases and no sales.

A typical purchase (the median) is worth €49k. For 3 purchases whose 90-day window has closed, the share price was higher on day 90 than the day after publication in 100% of cases, with a median move of +15.1%. This is a record of the past, not a forecast.

On 5 February 2014 came the latest disclosure, a transaction in Tvardi Therapeutics, Inc. The most recent open-market purchase was published on 5 February 2014, 4,644 days ago. Half of the filings or more reach the SEC (Form 4) feed on the day of the trade. The legal deadline for a Form 4 is two business days after the transaction. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.